Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Prevalence of multidrug resistance tuberculosis in adult patients in India: A systematic review and meta-analysis.

Charan J, Tank N, Reljic T, Singh S, Bhardwaj P, Kaur R, Goyal JP, Kumar A.

J Family Med Prim Care. 2019 Oct 31;8(10):3191-3201. doi: 10.4103/jfmpc.jfmpc_542_19. eCollection 2019 Oct.

2.

Corrigendum to 'Efficacy of allogeneic HCT in HTLV-1 associated adult T-cell leukemia/lymphoma: results of a systematic review/meta-analysis' [Biology of Blood and Marrow Transplantation 25/8 (2019) 1695-1700].

Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2020 Jan;26(1):209-212. doi: 10.1016/j.bbmt.2019.09.014. Epub 2019 Oct 11. No abstract available.

PMID:
31610149
3.

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis.

Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2020 Jan;26(1):76-82. doi: 10.1016/j.bbmt.2019.08.019. Epub 2019 Sep 5.

PMID:
31494227
4.

Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.

Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A.

Cancer. 2019 Dec 15;125(24):4417-4425. doi: 10.1002/cncr.32464. Epub 2019 Aug 23.

PMID:
31441943
5.

Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis.

Iqbal M, Reljic T, Klocksieben F, Sher T, Ayala E, Murthy H, Bazarbachi A, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1695-1700. doi: 10.1016/j.bbmt.2019.05.027. Epub 2019 May 25. Erratum in: Biol Blood Marrow Transplant. 2020 Jan;26(1):209-212.

PMID:
31132453
6.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.

Talati C, Dhulipala VC, Extermann MT, Ali NA, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE.

Haematologica. 2020 Jan 31;105(2):398-406. doi: 10.3324/haematol.2018.208637. Print 2020.

7.

Structured decision-making drives guidelines panels' recommendations "for" but not "against" health interventions.

Djulbegovic B, Reljic T, Elqayam S, Cuker A, Hozo I, Zhou Q, Li SA, Alexander P, Nieuwlaat R, Wiercioch W, Sch√ľnemann H, Guyatt G.

J Clin Epidemiol. 2019 Jun;110:23-33. doi: 10.1016/j.jclinepi.2019.02.009. Epub 2019 Feb 16.

PMID:
30779950
8.

Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis.

Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2019 Jul;54(7):1094-1106. doi: 10.1038/s41409-018-0393-0. Epub 2018 Nov 16.

PMID:
30446739
9.

Evidence to Decision framework provides a structured "roadmap" for making GRADE guidelines recommendations.

Li SA, Alexander PE, Reljic T, Cuker A, Nieuwlaat R, Wiercioch W, Guyatt G, Sch√ľnemann HJ, Djulbegovic B.

J Clin Epidemiol. 2018 Dec;104:103-112. doi: 10.1016/j.jclinepi.2018.09.007. Epub 2018 Sep 22.

PMID:
30253221
10.

Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis.

Kharfan-Dabaja MA, Reljic T, Murthy HS, Ayala E, Kumar A.

Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):703-709.e1. doi: 10.1016/j.clml.2018.07.295. Epub 2018 Aug 2.

PMID:
30145196
11.

Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk.

Sinkey RG, Lacevic J, Reljic T, Hozo I, Gibson KS, Odibo AO, Djulbegovic B, Lockwood CJ.

PLoS One. 2018 Apr 25;13(4):e0193169. doi: 10.1371/journal.pone.0193169. eCollection 2018.

12.

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval.

Djulbegovic B, Glasziou P, Klocksieben FA, Reljic T, VanDenBergh M, Mhaskar R, Ioannidis JPA, Chalmers I.

J Clin Epidemiol. 2018 Jun;98:24-32. doi: 10.1016/j.jclinepi.2018.01.011. Epub 2018 Feb 10. Review.

PMID:
29432860
13.

Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.

Charan J, Goyal JP, Reljic T, Emmanuel P, Patel A, Kumar A.

Pediatr Infect Dis J. 2018 Aug;37(8):773-780. doi: 10.1097/INF.0000000000001879.

14.

Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis.

Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A.

Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):53-64. doi: 10.1016/j.hemonc.2017.11.001. Epub 2017 Nov 26. Review.

15.

Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review.

Reljic T, Kumar A, Klocksieben FA, Djulbegovic B.

BMJ Open. 2017 Jan 6;7(1):e014661. doi: 10.1136/bmjopen-2016-014661. Review.

16.

Author Reply.

Charan J, Reljic T, Kumar A.

Indian J Pharmacol. 2016 Jul-Aug;48(4):467. No abstract available.

17.

Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review.

Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A.

Future Oncol. 2016 Nov;12(22):2631-2642. doi: 10.2217/fon-2016-0146. Epub 2016 Jul 6. Review.

PMID:
27381652
18.

Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review.

Charan J, Reljic T, Kumar A.

Indian J Pharmacol. 2016 Mar-Apr;48(2):186-91. doi: 10.4103/0253-7613.178839. Review.

19.

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis.

El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2016 May;22(5):802-14. doi: 10.1016/j.bbmt.2015.12.004. Epub 2015 Dec 20. Review.

20.

High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.

Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Aug;50(8):1144. doi: 10.1038/bmt.2015.126. No abstract available.

PMID:
26242579
21.

Thinking Styles and Regret in Physicians.

Djulbegovic M, Beckstead J, Elqayam S, Reljic T, Kumar A, Paidas C, Djulbegovic B.

PLoS One. 2015 Aug 4;10(8):e0134038. doi: 10.1371/journal.pone.0134038. eCollection 2015.

22.

Comparison of methodological quality of positive versus negative comparative studies published in Indian medical journals: a systematic review.

Charan J, Chaudhari M, Jackson R, Mhaskar R, Reljic T, Kumar A.

BMJ Open. 2015 Jun 24;5(6):e007853. doi: 10.1136/bmjopen-2015-007853. Review.

23.

High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.

Reljic T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA.

Bone Marrow Transplant. 2015 Aug;50(8):1069-74. doi: 10.1038/bmt.2015.69. Epub 2015 Apr 13. Review. Erratum in: Bone Marrow Transplant. 2015 Aug;50(8):1144.

PMID:
25867647
24.

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.

Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, Kumar A.

Cochrane Database Syst Rev. 2014 Jul 25;(7):CD010280. doi: 10.1002/14651858.CD010280.pub2. Review.

PMID:
25061777
25.

How do physicians decide to treat: an empirical evaluation of the threshold model.

Djulbegovic B, Elqayam S, Reljic T, Hozo I, Miladinovic B, Tsalatsanis A, Kumar A, Beckstead J, Taylor S, Cannon-Bowers J.

BMC Med Inform Decis Mak. 2014 Jun 5;14:47. doi: 10.1186/1472-6947-14-47.

26.

Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies.

Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A, Djulbegovic B, Kumar A, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1677-86. doi: 10.1016/j.bbmt.2014.05.017. Epub 2014 May 24. Review.

27.

Evaluation of Physicians' Cognitive Styles.

Djulbegovic B, Beckstead JW, Elqayam S, Reljic T, Hozo I, Kumar A, Cannon-Bowers J, Taylor S, Tsalatsanis A, Turner B, Paidas C.

Med Decis Making. 2014 Jul;34(5):627-37. doi: 10.1177/0272989X14525855. Epub 2014 Apr 10.

PMID:
24722474
28.

Treatment-related harms: what was planned and what was reported? National Cancer Institute's Co-operative group phase III randomized controlled trials: a systematic review.

Mhaskar RS, Reljic T, Wao H, Kumar A, Miladinovic B, Djulbegovic B.

J Clin Epidemiol. 2014 Mar;67(3):354-6. doi: 10.1016/j.jclinepi.2013.07.006. Epub 2013 Sep 19. Review. No abstract available.

PMID:
24055164
29.

Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.

Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):711-5. doi: 10.1016/j.clml.2013.07.007. Epub 2013 Sep 17.

PMID:
24054159
30.

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.

Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A.

Br J Haematol. 2013 Nov;163(3):315-25. doi: 10.1111/bjh.12528. Epub 2013 Aug 23. Review.

PMID:
24033280
31.

Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis.

Reljic T, Mahony H, Djulbegovic B, Etchason J, Paxton H, Flores M, Kumar A.

J Neurotrauma. 2014 Jan 1;31(1):78-98. doi: 10.1089/neu.2013.2873. Epub 2013 Nov 7. Review.

PMID:
23914924
32.

Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.

El-Jurdi N, Reljic T, Kumar A, Pidala J, Bazarbachi A, Djulbegovic B, Kharfan-Dabaja MA.

Immunotherapy. 2013 May;5(5):457-66. doi: 10.2217/imt.13.31. Review.

PMID:
23638742
33.

Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials.

Djulbegovic B, Kumar A, Miladinovic B, Reljic T, Galeb S, Mhaskar A, Mhaskar R, Hozo I, Tu D, Stanton HA, Booth CM, Meyer RM.

PLoS One. 2013;8(3):e58711. doi: 10.1371/journal.pone.0058711. Epub 2013 Mar 21.

34.
35.

New treatments compared to established treatments in randomized trials.

Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I.

Cochrane Database Syst Rev. 2012 Oct 17;10:MR000024. doi: 10.1002/14651858.MR000024.pub3.

36.

Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review.

Kumar A, Mhaskar AR, Reljic T, Mhaskar RS, Kharfan-Dabaja MA, Anasetti C, Mohty M, Djulbegovic B.

Leukemia. 2012 Apr;26(4):582-8. doi: 10.1038/leu.2011.349. Epub 2011 Dec 20. Review.

PMID:
22182922

Supplemental Content

Loading ...
Support Center